The Jumpstarting Brain Tumor Drug Development Coalition (JBTDDC) is offering a new consensus protocol for magnetic resonance imaging (MRI) in brain tumor clinical trials to help in the assessment of whether a new treatment is effective.
Aspect Magnetic Technologies claim its new compact M2 magnetic resonance imaging (MRI) systems “help preclinical researchers expand the horizons for completely new ideas and discovery.”
France-based CRO Cellvax has moved to a new laboratory to provide clients with large animal services and new technical platforms, such as scintigraphy, histological analysis and biomarkers.
Perceptive Informatics has expanded its offering for trials involving Alzheimer's disease with a new medical imaging method, which it claims produces higher quality, reproducible and regulatory compliant assessments.
Charles River Laboratories has agreed to buy US-based drug discovery imaging expert Molecular Imaging Research, Inc. (MIR) for approximately $12.5m (€8.8m) in cash.
Researchers have found a new technique that allows stem cells to be
tracked as they move through the body, potentially allowing a
greater understanding of regenerative medicines.
Using a modified version of nuclear magnetic resonance technology,
(NMR) scientists have revealed the therapeutic potential of an
insect's venom, which could be utilised to provide a better
understanding of Alzheimer's disease...
A recent report claims that nanobiotechnology is under growing
pressure to fulfil its potential and repay the private and public
funding that has been invested towards this emerging science
sector.
